PureTech Health (NASDAQ:PRTC) Trading Down 0.7% - Time to Sell?

Shares of PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - Get Free Report) dropped 0.7% during mid-day trading on Tuesday . The stock traded as low as $16.91 and last traded at $16.70. Approximately 900 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 1,977 shares. The stock had previously closed at $16.81.Get PureTech Health alerts:Analyst Ratings ChangesSeparately, Weiss Ratings reiterated a "sell (d)" rating on shares of PureTech Health in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of "Sell".Read Our Latest Stock Analysis on PRTCPureTech Health Trading Down 0.7%The firm's 50-day moving average price is $17.09 and its 200-day moving average price is $17.60. Hedge Funds Weigh In On PureTech HealthLarge investors have recently modified their holdings of the stock. Persistent Asset Partners Ltd bought a new stake in PureTech Health in the second quarter worth $29,000. Diadema Partners LP bought a new stake in shares of PureTech Health in the 2nd quarter worth about $126,000. Pentwater Capital Management LP boosted its stake in shares of PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock worth $664,000 after purchasing an additional 9,449 shares during the period. Finally, Lansdowne Partners UK LLP bought a new position in PureTech Health during the 3rd quarter valued at about $260,973,000. Institutional investors own 0.04% of the company's stock. About PureTech Health (Get Free Report)PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.See AlsoFive stocks we like better than PureTech HealthTSX Venture Exchange (Formerly Canadian Venture Exchange)Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart BuyInvesting in the High PE Growth Stocks RTX Surges to Record Highs as Defense Orders ExplodeBusiness Services Stocks InvestingSmart Money Is Buying Auto Suppliers, Not Car BrandsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in PureTech Health Right Now?Before you consider PureTech Health, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.While PureTech Health currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here